Our Business
Our Business
SANBS' funding model depends entirely on cost recovery from the Department of Health (DoH) and medical schemes. Although medical schemes must legally hold 25% cash reserves, SANBS deliberately maintains a >50% reserve buffer. This prudent approach safeguards our ability to continue operations, and critically to supply lifesaving blood products, should we be faced with operational challenges or prolonged non-payment from the DoH and medical schemes.
Accreditation excellence - In achieving ISO 9001, ISO 17043 and ISO 13485 accreditation, SANBS completed the 5-year journey of harmonisation of accreditation standards. Together with our ISO 15189 accreditation (the main accreditation standard in SANBS), ISO 20387, Joint Accreditation Committee ISCT-EBMT (JACIE) and our European Federation for Immunogenetics (EFI), SANBS now has a full suite of accreditation for all our business processes, a testament to our commitment to quality.
Innovation in platelet supply - To address the high cost and limited availability of apheresis platelets, we piloted leucocyte reduced pooled platelets in two zones, a product known for equivalent efficacy but at a lower cost than apheresis platelets. The project was rolled out to our other zones and clinicians were trained on the new product.
Addressing process gaps and staff errors - Incidents of administrative errors, stemming from the need for manual transcription, insufficient or inadequate equipment and staff understanding of newly implemented processes, prompted a comprehensive corrective response. We launched a major intervention to address equipment and connectivity challenges, streamline digital processes, eliminate where possible, manual steps and embed stronger process controls. These activities were underpinned by extensive staff engagement and retraining where required. In response, we noted a steep decline in errors.
The National Haemovigilance Committee was implemented as a joint initiative between SANBS and Western Cape Blood Service (WCBS). Their role is to independently review the serious donor and patient adverse events reported to SANBS and WCBS and provide their input to the Clinical Governance Committee. This has ensured an extra layer of assurance of our commitment to donor and patient safety.
As we embed ‘Serving with Heart’ across the company, our medical and technical priorities include:
Expanding our donor base to ensure sustainability into the future, given the country’s shifting demographics and healthcare needs
Building deeper engagement with specialised physician groups in neurology, stem cell transplants, and bone marrow registry work
Strengthening relationships with HPCSA and SANC to resolve accreditation and training bottlenecks for technologists and phlebotomists
Formalising data governance and information management to improve accuracy, security, and decision-making
Leveraging technology to automate laboratory processes and mitigate the impact of scarce specialised skills
Implementing a succession plan to ensure continuity of medical leadership and technical expertise
I am incredibly proud of the dedication, skill, and empathy demonstrated by our teams this year. Managing an organisation as complex as ours requires a remarkable blend of diverse skills, experience, and exceptional leadership capability to execute our mandate to save lives.
To our donors, your generosity is the heartbeat of SANBS. To our employees, thank you for combining clinical excellence with care and compassion. To our partners across South Africa and Africa, your collaboration strengthens our shared mission. We remain steadfast in our support for patients and their doctors, committed to delivering the highest standard of care.
As we step into this new chapter, we carry forward not just our technical expertise, but the heart of service that defines who we are.